|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Full length recombinant human MAGE-1 protein|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
MA5-12477 targets MAGE-1 in IHC (P) applications and shows reactivity with Human samples.
The MA5-12477 immunogen is full length recombinant human MAGE-1 protein.
Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor-directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). An important group of antigens is coded by the MAGE family of genes. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival.
MA5-12477 was used in western blot to investigate the role of CT16 in melanoma cell survival
|Nylund C,Rappu P,Pakula E,Heino A,Laato L,Elo LL,Vihinen P,Pyrhönen S,Owen GR,Larjava H,Kallajoki M,Heino J||PloS one (7:null)||2012|